Datapoint

Datapoint: FDA Approves Second Drug for Rare Neuromuscular Disorder

May 14, 2019

The FDA last week approved Jacobus Pharmaceuticals’ Ruzurgi for the treatment of Lambert-Eaton myasthenic syndrome (or LEMS), a rare neuromuscular disorder. Only one other drug is approved to treat LEMS, Catalyst Pharmaceuticals’ Firdapse, which currently holds preferred status for 7% of covered lives, and is not covered for 11% of lives. Firdapse made waves for its $375,000 list price when it was approved in December. Pricing information for Ruzurgi has not yet been released.

The FDA last week approved Jacobus Pharmaceuticals’ Ruzurgi for the treatment of Lambert-Eaton myasthenic syndrome (or LEMS), a rare neuromuscular disorder. Only one other drug is approved to treat LEMS, Catalyst Pharmaceuticals’ Firdapse, which currently holds preferred status for 7% of covered lives, and is not covered for 11% of lives. Firdapse made waves for its $375,000 list price when it was approved in December. Pricing information for Ruzurgi has not yet been released.

SOURCE: MMIT Analytics, as of 5/9/19

Datapoint: CareSource Partners With Altruista Health

May 13, 2019

CareSource, the seventh-largest managed Medicaid insurer in the U.S., last week said it will partner with Altruista Health to provide care management solutions across all of its plans. The insurer currently serves 1,638,154 Medicaid and CHIP members in four states. CareSource will have access to Altruista’s GuidingCare member platform, which allows interdisciplinary care teams to collaborate and communicate effectively to manage members’ myriad needs.

CareSource, the seventh-largest managed Medicaid insurer in the U.S., last week said it will partner with Altruista Health to provide care management solutions across all of its plans. The insurer currently serves 1,638,154 Medicaid and CHIP members in four states. CareSource will have access to Altruista’s GuidingCare member platform, which allows interdisciplinary care teams to collaborate and communicate effectively to manage members’ myriad needs.

Source: AIS’s Directory of Health Plans

Datapoint: Pfizer’s New Heart Drug Scores FDA Nod, Lower Price Than Competitors

May 9, 2019

Despite a previous rejection, the FDA this week approved Pfizer’s Vyndaqel (and sister formulation Vyndamax) for the treatment of both hereditary and spontaneous ATTR cardiomyopathy (ATTR-CM), a rare and deadly form of heart disease. Pfizer’s drug stands to face two rivals, Alnylam’s Onpattro and Ionis’s Tegsedi, if it can score an additional FDA approval for hereditary ATTR polyneuropathy (hATTR-PN). Onpattro is also working to score an ATTR-CM nod. For the treatment of hATTR-PN, both rival drugs hold preferred status for only 1% of covered lives. Pfizer’s drug has a much lower list price than its competitors ($225,000 per year vs. $450,000) and is an oral pill, while Onpattro and Tegsedi are both injectables.

Despite a previous rejection, the FDA this week approved Pfizer’s Vyndaqel (and sister formulation Vyndamax) for the treatment of both hereditary and spontaneous ATTR cardiomyopathy (ATTR-CM), a rare and deadly form of heart disease. Pfizer’s drug stands to face two rivals, Alnylam’s Onpattro and Ionis’s Tegsedi, if it can score an additional FDA approval for hereditary ATTR polyneuropathy (hATTR-PN). Onpattro is also working to score an ATTR-CM nod. For the treatment of hATTR-PN, both rival drugs hold preferred status for only 1% of covered lives. Pfizer’s drug has a much lower list price than its competitors ($225,000 per year vs. $450,000) and is an oral pill, while Onpattro and Tegsedi are both injectables.

SOURCE: MMIT Analytics, as of 5/8/19

Datapoint: Livongo and Cambia to Launch Medicare Advantage Partnership

May 8, 2019

CMS last week said it has approved Livongo, a technology company that provides solutions for diabetes and hypertension patients, to become a Medicare Advantage provider for Cambia Health Solutions. Cambia’s MA members will become eligible to start using Livongo’s diabetes program in June. Cambia currently enrolls 94,024 Medicare Advantage lives across its Regence BlueShield and other branded products.

CMS last week said it has approved Livongo, a technology company that provides solutions for diabetes and hypertension patients, to become a Medicare Advantage provider for Cambia Health Solutions. Cambia’s MA members will become eligible to start using Livongo’s diabetes program in June. Cambia currently enrolls 94,024 Medicare Advantage lives across its Regence BlueShield and other branded products.

Source: AIS’s Directory of Health Plans

Datapoint: Capital BlueCross to Form Strategic Partnership With WellSpan Health

May 7, 2019

Pennsylvania-based Capital BlueCross said it has entered a long-term agreement to form a strategic partnership with WellSpan Health, an integrated system of eight hospitals and more than 170 patient care facilities throughout Pennsylvania and Maryland. The two entities plan to launch new Medicare Advantage products, and will aim to more closely coordinate care delivery, enhancing benefits and creating new digital health strategies. Financial details of the arrangement were not disclosed. Capital BlueCross currently enrolls 696,572 lives in Pennsylvania, with 43.2% of members enrolled in risk-based commercial products.

Pennsylvania-based Capital BlueCross said it has entered a long-term agreement to form a strategic partnership with WellSpan Health, an integrated system of eight hospitals and more than 170 patient care facilities throughout Pennsylvania and Maryland. The two entities plan to launch new Medicare Advantage products, and will aim to more closely coordinate care delivery, enhancing benefits and creating new digital health strategies. Financial details of the arrangement were not disclosed. Capital BlueCross currently enrolls 696,572 lives in Pennsylvania, with 43.2% of members enrolled in risk-based commercial products.

Source: AIS’s Directory of Health Plans

Datapoint: FDA Approves Second Enbrel Biosimilar

May 6, 2019

The FDA on April 26 approved a second biosimilar for Amgen Inc.’s Enbrel, Samsung Bioepis’ Eticovo, sacross all of Enbrel’s indications. Enbrel’s first biosimilar, Sandoz’s Erelzi, was approved in 2016, but has yet to hit the market as Amgen is fighting the drug’s U.S. launch in court. For the treatment of rheumatoid arthritis, Enbrel holds preferred formulary status for 7% of covered lives, which grows to 49% with the inclusion of step therapy and/or prior authorization requirements.

The FDA on April 26 approved a second biosimilar for Amgen Inc.’s Enbrel, Samsung Bioepis’ Eticovo, sacross all of Enbrel’s indications. Enbrel’s first biosimilar, Sandoz’s Erelzi, was approved in 2016, but has yet to hit the market as Amgen is fighting the drug’s U.S. launch in court. For the treatment of rheumatoid arthritis, Enbrel holds preferred formulary status for 7% of covered lives, which grows to 49% with the inclusion of step therapy and/or prior authorization requirements.

SOURCE: MMIT Analytics, as of 5/1/2019